| Type | Title | Date Released | |
|---|---|---|---|
SCHEDULE 13G/A | Soleus Capital Master Fund, L.P. (Filed by) New | ||
10-Q | Form 10-Q | ||
8-K | Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth | ||
4 | MOATAZEDI DAVID (Reporting) | ||
144 | Form 144 | ||
SCHEDULE 13G | Soleus Capital Master Fund, L.P. (Filed by) | ||
10-Q | Form 10-Q | ||
8-K | Evolus Reports Strong Second Quarter 2026 Financial Results and Raises Full-Year 2026 Outlook | ||
8-K | Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand | ||
8-K | Evolus Enters Exclusive Agreement with IBSA to Commercialize Profhilo® in the U.S. | ||
EFFECT | Form EFFECT | ||
8-K | Evolus, Inc. Announces Results of 2026 Annual Meeting of Stockholders |
